Showing 9431-9440 of 20873 results for "".
Updates on Breast Cancer Treatment: Exploring CDK4/6 Inhibitors & Endocrine Therapy
https://reachmd.com/programs/project-oncology/updates-on-breast-cancer-treatment-exploring-cdk46-inhibitors-endocrine-therapy/13760/When breast cancer progresses for patients on a CDK4/6 inhibitor, should we switch to endocrine therapy?Investigating Esophageal Strictures
https://reachmd.com/programs/gi-insights/investigating-esophageal-strictures/13747/How can we improve the treatment of benign esophageal strictures?The Emerging Role of Immunotherapy in Triple-Negative Breast Cancer
https://reachmd.com/programs/project-oncology/the-emerging-role-of-immunotherapy-in-triple-negative-breast-cancer/13750/As immunotherapy begins to move into the field of triple-negative breast cancer, what do we need to know?Not the Average Investor
https://reachmd.com/topics/practice-development/not-the-average-investor/35173/Why physicians need a different approach to investingA Guide for Deprescribing Proton Pump Inhibitors
https://reachmd.com/programs/gi-insights/a-guide-for-deprescribing-proton-pump-inhibitors/13683/Since the overuse of proton pump inhibitors has been associated with adverse events, here’s how we can deprescribe them in appropriate patients.Proton Pump Inhibitors: Overused or Necessary?
https://reachmd.com/programs/gi-insights/proton-pump-inhibitors-overused-or-necessary/13467/Proton pump inhibitors are among the most frequently prescribed medications in the world. But are they always a necessary prescription?Evaluating & Treating IBD in the Elderly
https://reachmd.com/programs/gi-insights/evaluating-treating-ibd-in-the-elderly/13318/Inflammatory bowel disease among the elderly is common and has an increased risk of mortality. So how can we achieve better outcomes for our patients?Catching Complications in IBD: How to ID Those at Risk
https://reachmd.com/programs/gi-insights/catching-complications-in-ibd-how-to-id-those-at-risk/12781/Predicting which patients with IBD will develop complications allows for much better medication choices. But how do we go about predicting that risk?IBD & COVID-19: How to Manage Patients Amid the Pandemic
https://reachmd.com/programs/gi-insights/ibd-covid-19-how-to-manage-patients-amid-the-pandemic/12581/From medications to vaccinations, here’s a collection of best practices for managing patients with IBD amid the COVID-19 pandemic.Is It Time to Reexamine the Role of Anti-TNFs in the IBD Landscape?
https://reachmd.com/programs/gi-insights/is-it-time-to-reexamine-the-role-of-anti-tnfs-in-the-ibd-landscape/12342/Now that we have therapies like vedolizumab and ustekinumab, many are wondering if there’s still a role for anti-TNFs in the treatment of IBD.